New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression

Sugandha Bhatia1,2*, Peiyu Wang1,2, Alan Toh1,2 and Erik W. Thompson1,2

1 Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Qld, Australia, 2 Translational Research Institute, Brisbane, Qld, Australia

Tumor cells demonstrate substantial plasticity in their genotypic and phenotypic characteristics. Epithelial-mesenchymal plasticity (EMP) can be characterized into dynamic intermediate states and can be orchestrated by many factors, either intercellularly via epigenetic reprogramming, or extracellularly via growth factors, inflammation and/or hypoxia generated by the tumor stromal microenvironment. EMP has the capability to alter phenotype and produce heterogeneity, and thus by changing the whole cancer landscape can attenuate oncogenic signaling networks, invoke anti-apoptotic features, defend against chemotherapeutics and reprogram angiogenic and immune recognition functions. We discuss here the role of phenotypic plasticity in tumor initiation, progression and metastasis and provide an update of the modalities utilized for the molecular characterization of the EMT states and attributes of cellular behavior, including cellular metabolism, in the context of EMP. We also summarize recent findings in dynamic EMP studies that provide new insights into the phenotypic plasticity of EMP flux in cancer and propose therapeutic strategies to impede the metastatic outgrowth of phenotypically heterogeneous tumors.

Keywords: EMT, EMP, stem cell, CTCs, hybrid EMT states, metastasis, metabolism, tumor cell heterogeneity

INTRODUCTION (EMT-MET)

Epithelial–mesenchymal transition (EMT), in which epithelial cells undergo dynamic cellular transition from a sessile epithelial state to a motile mesenchymal state allowing the formation of new tissues, is considered one of the pivotal processes during embryogenesis and organogenesis (Chaffer et al., 2007; Yang and Weinberg, 2008). The process of EMT (classified as three different subtypes) has been implicated in a broad range of normal and pathophysiological processes from development, wound healing and tissue regeneration (type 1), to organ fibrosis (type 2), and cancer progression (type 3) (Kalluri and Weinberg, 2009). During cancer progression, it is postulated that epithelial-derived carcinoma cells undergo a reversible, trans-differentiation process with changes in cell–cell adhesion and polarity, cytoskeletal remodeling, migratory and invasive enhancement, and dissemination into secondary organs via local invasion, intravasation and transfer through the blood stream and lymphatics (Polyak and Weinberg, 2009). In addition to cellular migration during metastasis, EMT also influences resistance to anoikis and apoptosis, blocks senescence, enhances survival, facilitates genomic instability, causes cancer stem cell (CSC) activity, alters
metabolism, and induces drug resistance and immune suppression (Przybylo and Radisky, 2007; Anseau et al., 2008; Gal et al., 2008; Kumar et al., 2011; Huang et al., 2013; Dongre et al., 2017; Lee et al., 2018; Redfern et al., 2018).

After invasion and spread, cancer recurrence at the metastatic site is thought to require the reverse process, termed mesenchymal to epithelial transition (MET) (Chaffer et al., 2007; Hugo et al., 2007; Brabletz, 2012). The reversal of EMT, referred to as MET, has received less attention than EMT in the establishment of metastasis. Microenvironmental cues are considered a major deterministic factor for the reversion of the migratory mesenchymal neoplastic cells and the subsequent development of macrometastases. However, the re-expression of E-cadherin, inhibition of SNAIL, and β-catenin sequestration have provided evidence of MET in liver metastasis from MDA-MB-231 (Chao et al., 2010; Brabletz, 2012), as has the anti-metastatic effects of sustained pro-mesenchymal signals (Ocana et al., 2012; Tsai et al., 2012). The concept of MET in metastasis is refuted in some of the cancer recurrence studies as no definitive proof of a MET requirement was obtained in the MMTV-PyMT genetically engineered mouse model (GEMMs) of metastatic breast cancer or in the KPC GEMM for metastatic pancreatic cancer (Fischer et al., 2015; Zheng et al., 2015). Nevertheless, recent data on EMP phenomena during metastatic cancer colonization is emerging (Chao et al., 2010; Rhim et al., 2012; Nieto, 2013; Beerling et al., 2016; Pastushenko et al., 2018) and could be of particular interest in breast and pancreatic carcinomas where MET is considered an early event in tumorigenesis (Hüsemann et al., 2008; Rhim et al., 2012). Moreover, other studies have reported at least partial involvement of EMP in the breast model (Ye et al., 2015) and Zeb1 has been shown to contribute to metastasis in the pancreatic model (Krebs et al., 2017).

Considerably less information is available on the key intrinsic factors that drive MET in vivo and in vitro, while the drivers and transcriptional mediators of EMT are quite comprehensively documented (Stemmller et al., 2019). Bone morphogenetic protein 7 (BMP7) is reported to trigger MET in renal fibroblasts during kidney development (Zeisberg et al., 2005), and also in breast cancer cells, reducing their capability to form bone metastases (Buijs et al., 2007). Protein Kinase A was recently identified as an inducer of MET in human mammary epithelial cells (Pattabiraman et al., 2016). The role of Notch4 in melanoma cells to induce MET and suppress malignancy in mice has also been reported (Bonyadi Rad et al., 2016). The course of epigenetic reprogramming is also supporting EMT and MET acquisition (Tamura et al., 2000). Reversible epigenetic changes acquired during EMT underpin the emergence of self-renewal and chemo-refractory stem cell-like features, which can revert to the MET phenotype for establishing metastasis (Voulgaris and Pintzas, 2009; Sharma et al., 2010). Here, we discuss the role and the regulatory mechanisms of EMP, with the focus on recent emerging concepts that highlights the bidirectional dynamics of this phenomenon and the hybrid intermediate states. We also provide a brief overview of various techniques/modalities employed to analyze EMP in cancer. Understanding the phenotypic plasticity will provide insights for various therapeutic strategies that can be implemented to prevent/restrict spread of cancer by metastasis.

**SIGNIFICANCE OF EMP AND HYBRID EMT STATES**

Epithelial–mesenchymal transition, however, is not a two-step event through which cancer cells lose epithelial markers and acquire mesenchymal traits between two rigid phenotypes. Rather, studies performed within the last decade increasingly show that cancer cells sequentially acquire mesenchymal traits, but don't automatically dissipate all of their previously expressed epithelial features (Tam and Weinberg, 2013; Aiello and Kang, 2019). The term “epithelial–mesenchymal plasticity” (EMP) is more favored recently as compared to EMT-MET (Bhatia et al., 2017; Williams et al., 2019). The multiple signal transduction cascade for EMT-MET programing results in dynamic and intermediate transitional states wherein, the cancer cells can reside in all three EMP phenotypes (epithelial, mesenchymal and hybrid phenotype). EMP reflects the bidirectional flux often in a continuum across the full spectrum (Lee et al., 2006; Oltean et al., 2006). Thus, a full spectrum of EMP endows the formation of a new carcinomatous tumor at distant organ sites with similar histopathology as observed in primary tumor (Gunasinghe et al., 2012).

Hybrid epithelial-mesenchymal features of carcinoma cells have indeed been observed in various invasive carcinoma model systems (Lee et al., 2006; Klymkowsky and Savagner, 2009), in which individual cells co-express markers of both epithelial and mesenchymal lineages, and circulating tumor cells (CTCs) in particular have been shown to exhibit a spectrum of EMP states (Armstrong et al., 2011; Yu et al., 2014; Khoo et al., 2015; Bourcy et al., 2016); reviewed in McInnes et al. (2015); Hassan et al. (2020). The hybrid EMP state seen in carcinomas and CTCs, in which individual cells co-express markers of both epithelial and mesenchymal lineages, is predicted to have the highest tumourigenicity and metastatic potential (Lee et al., 2006; Klymkowsky and Savagner, 2009; Jolly et al., 2016; Kroger et al., 2019; Pastushenko and Blanpain, 2019). An emerging challenge is also to decipher correctly the contribution that intermediate states of the EMP spectrum make to tumor evolution for therapeutic interventions.

**EXTRINSIC AND INTRINSIC MECHANISMS AND REGULATORS INVOLVED IN PLASTICITY**

The crosstalk mediated by autocrine and/or paracrine factors secreted by cancer cells and tumor stroma has been widely proven to occur via extracellular mediators of EMT (Scheel et al., 2011). A host of extracellular mediators secreted by tumor stromal cells are already proven to elicit EMT induction. Examples of validated extracellular mediators as EMT inducers include TGF-β (Buonato et al., 2015), EGF (Hugo et al., 2009), FGF (Kurimoto et al., 2016), PDGF (Devarajan et al., 2012),
HGF (Suarez-Causado et al., 2015), IGF (Wang et al., 2016), Interleukin-6 (IL-6) (Miao et al., 2014), WNT (Ochoa-Hernandez et al., 2012), Hedgehog (Yoo et al., 2011), and Notch (Yuan et al., 2014). Other inducers of EMT include collagen types I and III, matrix metalloproteinases-2 (MMP-2), MMP-3, MMP-9, and MMP14/MT1-MMP (Thiery et al., 2009). YAP and TAZ are also emerging as key modulators in inducing plasticity and skin cancer initiation (Moroishi et al., 2015; Debaugnies et al., 2018). EMT of tumor cells can also be induced by various stimuli from the tumor microenvironment (Marcucci et al., 2014); Fabrizio Marcucci and his colleagues proposed five major classes of these stimuli in 2016 (Marcucci et al., 2016): hypoxia and low pH, innate and adaptive immune responses, mechanical stress, altered ECM and treatment with chemotherapeutics (Figure 1).

Interestingly, hypoxic features in the tumor microenvironment can stimulate EMT as a downstream consequence of upregulated hypoxia-inducible factor 1α (HIF1α) (Wong et al., 2012). Apart from tumor microenvironment stimuli for EMT induction, stimulus-independent activation of signaling pathways, caused by mutations or epigenetic modifications leading to overexpression of certain pathway components, can also trigger EMT (Wallin et al., 2012; Serrano-Gomez et al., 2016). Gain-of-function mutations in P53 has been reported to induce EMT via modulation of miR-130b-Zeb1 axis (Dong P. et al., 2013).

Epigenetic modifications can also cause a shift of epithelial to mesenchymal state; for example, aberrant DNA CpG island methylation correlated with the repression of the miR-200 cluster, which promotes EMT and contributes to tumor progression (Vrba et al., 2010). LSD1-dependent genome-scale epigenetic reprogramming was also observed during EMT (McDonald et al., 2011; Tang et al., 2013; Boulding et al., 2019). Various other chromatin regulators (e.g., DNMT1, KDM6B, PHF8, EZH2, and HDAC) are also reported to regulate EMT, genomic stability and metastasis (Suvà et al., 2013; Lu and Kang, 2019). Apart from epigenetics and mutations, EMT can also be modulated at transcriptional, post-transcriptional, translational and post-translational levels. The intrinsic gene network regulators, via alternate splice isoforms of ESRP1/2, microRNAs and long non-coding RNAs, also acts as other distinctive mechanisms to induce EMT (Aiello et al., 2018; Aiello and Kang, 2019). It has been postulated that during chemotherapy regimens, undifferentiated cancer cells also commence EMT, causing therapy resistance, CSC-like behavior, and a high propensity for metastasis. Tumor relapse after drug treatment cessation is due to persistence of disseminated CSC with mesenchymal features (Witta et al., 2006). Redfern et al. (2018) have also recently shown shorter overall survival times in patients treated with EMT-inducing agents compared to agents known to inhibit EMT.

The expression changes of various key molecular markers during EMT, are represented in Figure 1 (Christiansen and Rajasekaran, 2006; Pastushenko and Blanpain, 2019). The transition of epithelial cells to a more mesenchymal state is characterized by reduced intracellular adhesion through the downregulation of E-cadherin (CDH1) and EpCAM, and gain of mesenchymal markers such as N-cadherin (CDH2), vimentin and FSP1/S100A4 (Francart et al., 2018). Repressors of E-cadherin can be divided into groups that modulate either directly or indirectly effects on gene transcription by binding to promoter sites. ZEBs, SNAIL1 and KLF8 repress expression by binding the E-cadherin promotor, thereby inactivating transcription, while E2.2, FOXC2, GOOSECOID, and TWIST repress E-cadherin transcription as indirect repressors (Peinado et al., 2004, 2007; Xu et al., 2019). These factors also share an elaborate interactome, in that SNAIL1 upregulates SNAIL2 and TWIST (Thuault et al., 2008; Smit et al., 2009), SNAIL1 and TWIST then induce ZEB1 and SNAIL2 (Casas et al., 2011; Dave et al., 2011), and SNAIL2 induces ZEB2 (Thuault et al., 2008). Although commonly serving as repressors of E-cadherin, these broader mechanisms also selectively modulate other programs.

**FIGURE 1** | Major categories of EMP stimuli and markers involved in EMP. The dynamics of the epithelial–mesenchymal spectrum can be induced by five major stimuli (hypoxia, immuno-modulators, mechanical stress, altered ECM, and chemotherapeutics), which involve changes in various functional and morphological states and enlisted markers across the spectrum of epithelial-mesenchymal plasticity. ECM, extracellular matrix.

1. Hypoxia and low pH
2. Immuno-modulation
3. Mechanical stress
4. Altered ECM
5. Chemo-therapeutics

E-cadherin
ZO-1
Ocludin
miR-200
Claudin3,4,7
BMP7
Notch4
OVOL2
GRHL2

Epithelial state
Mesenchymal state
involved in cell division, cell survival, and cell attachment, thereby resulting in a motile, invasive and resistant cell phenotype (Barrallo-Gimeno and Nieto, 2005).

ROLE OF EMT IN TUMOR INITIATION, PROGRESSION AND METASTASIS

Although much less studied than later tumor stages, a number of studies have made a connection between the linkage of EMT to stemness and tumor-initiating capacity (Mani et al., 2008; Morel et al., 2008). In some carcinoma cells, overexpression of EMT transcription factors (EMT-TFs) has been observed to drive and enhance tumorigenicity (Wellner et al., 2009), and in particular, EMT has been shown to cause avoidance of oncogene-induced senescence (Anseau et al., 2008). In a mouse skin SCC model, low levels of TWIST was explicitly responsible for the tumor initiation process, whereas higher levels of TWIST induced EMT and tumor progression (Beck et al., 2015). In recent lineage tracing studies along with transcriptional and epigenomic profiling, Latil et al found disparities in the tumors generated from interfollicular epidermis (IFE) and hair follicle (HF) stem cells (Lgr5CreER). While IFE tumors showed a well-differentiated phenotype, tumors generated from HF stem cells displayed an EMT spectrum and increased metastatic potential (Latil et al., 2017).

The profound role of EMP in tumor progression and metastasis in vivo has remained a topic with various controversies (Brabletz et al., 2018; Williams et al., 2019). The number of mesenchymal cells observed in primary cancers in many xenograft studies had been observed to be less than 10%. Although the specific dissemination process of these cells is not yet well documented (Bhatia et al., 2019; Lourenco et al., 2020), enrichment of EMT in circulating tumor cells has supported a role for EMT in the initial steps of metastasis. Various studies have highlighted the role of key EMT TFs, such as Slug and Zeb1, in promoting metastasis of breast and colorectal cancer to liver and lung, respectively (Spaderna et al., 2008; Guo et al., 2012). Downregulation of TWIST expression in highly metastatic mammary carcinoma cells was found to inhibit their metastatic seeding ability in the lung (Yang et al., 2004). However, these studies are nuanced by observations that enforced overexpression or downregulation of EMT-TFs doesn’t recapitulate the dynamic spectrum of transitional and/or partial EMT states discovered in vivo (Pastushenko et al., 2018). Similarly, the studies from the genetic abrogation of Twist or Snail in mouse models of pancreatic adenocarcinoma and from EMT lineage tracing using Fsp1 and β-actin promoter in breast cancer mouse model have questioned the indispensability of full mesenchymal transition in the metastasis process (Fischer et al., 2015; Zheng et al., 2015). The conclusions of these studies have been subsequently refuted by other studies where genetic depletion of Zeb1 in the same pancreatic model resulted in strong suppression of metastasis. Therefore, caution is required while interpreting such results as the context of EMT and other compensatory mechanisms may significantly influence their role in promoting metastasis (Aiello et al., 2017; Ye et al., 2017). With the advent of cell fate mapping studies using intra-vital imaging, plasticity was revealed in mouse breast tumor cells from primary site to its re-epithelisation upon metastasis (Beerging et al., 2016). Several other studies have also reported the direct evidence of EMP under physiological conditions (Rhim et al., 2012; Chaffer et al., 2013; Ye et al., 2015). Multiple tumor subpopulations screened from mammary and skin tumors suggested that tumor cells with hybrid phenotypes were more efficient in dissemination and metastasis (Pastushenko et al., 2018; Thompson and Nagaraj, 2018; Pastushenko and Blanpain, 2019; Rios et al., 2019). Similar, other relevant studies are also emerging to suggest that cancer cells mostly transition between epithelial/mesenchymal and hybrid intermediate states, but rarely undergo complete EMT during metastasis (Kroger et al., 2019).

EMP ANALYSIS OF CIRCULATING TUMOR CELLS (CTCS)

Generation of CTCs is regarded as a consequential effect of the multi-step processes that constitute the metastatic cascade (Lambert et al., 2017), and have become a particularly rich source of evidence and information regarding the role of EMP in cancer progression. Understanding the biology and characteristics of CTCs can provide important insights into the molecular and cellular requirements of cancer cells during metastatic spread. Observations of enriched levels of mesenchymal genes (e.g., N-cadherin, vimentin and Twist) and reduced expression of epithelial genes (e.g., E-cadherin, EpCAM and CK8/18/19) has been reported in the CTCs relative to cells in the tumors of origin in the breast cancer patients (Yu et al., 2013; Wang et al., 2018). Although many CTCs exhibit a mesenchymally enriched phenotype, some researchers have revealed that a small population of CTCs co-expressed both epithelial and mesenchymal (E/M) hybrid phenotype traits, which likely promoted cell migration, cell invasion and cell survival capabilities (Lecharpentier et al., 2011; Milano et al., 2018). Hence hybrid CTCs may be more metastatic than mesenchymal CTCs.

High numbers of CTCs in blood is significantly associated with poor prognosis in several carcinoma types, such as prostate cancer (Wang et al., 2011), breast cancer (Buljoni et al., 2016), pancreatic cancer (Han et al., 2014), lung cancer (Naito et al., 2012), and increasingly these have taken account of CTC phenotypes (Tachtsidis et al., 2016). Pan et al. (2019) conducted a correlation study between CTC phenotypes and clinicopathological features of early cervical cancer, finding lower CTC counts in stage I patients than stage II patients with pelvic lymph node metastasis, but also that mesenchymal CTCs expressing vimentin and TWIST were more commonly found in the latter. Consistently, Markiewicz et al. (2014) selectively found of VIM, SNAI1, and UPAR expression in mesenchymal CTCs derived from breast cancer patient with lymph nodes metastases. Due to the low number of CTCs in blood, the greatest challenge in studying CTCs is the detection and isolation of these cells from patients’ blood (Kowalik et al., 2017). Molecular profiling of EMT markers in CTCs has been used to establish tools to isolate
and classify CTCs. RNA in situ hybridization (RNA-ISH) is a detection method that employs specific probes targeting different epithelial and mesenchymal genes to detect multiple transcripts simultaneously (Lopez-Munoz and Mendez-Montes, 2013). An enhanced RNA-ISH-based detection system, CTCscope, was innovated to detect eight epithelial markers and three EMT markers (Payne et al., 2012), and has been employed successfully in the landmark breast cancer CTC study (Yu et al., 2013; Wang et al., 2018). The FDA-approved CELLSEARCH® system (Menarini-Silicon Biosystems, Inc.), which immunocaptures EpCAM-expressing CTCs for patient prognosis (Riethdorf et al., 2007), is intrinsically biased toward predominately epithelial CTCs. However, recent CTC studies have employed microfluidic devices to capture and isolate CTCs according to their size and deformability, which allows for better coverage of different phenotypic states (Lemaire et al., 2018; Ribeiro-Samy et al., 2019).

Although the devices used to isolate CTCs have improved the quality and quantity assessment of CTCs, there are still limitations when studying CTCs. Over the past few years, use of the revolutionary single-cell RNA sequencing (scRNA-seq) has emerged to assess genome-wide expression profiles of isolated CTC populations and CTC clusters. Aceto et al. (2014) conducted scRNA-seq on endogenous CTCs generated using tumor xenografts of LM2 variant of MDA-MB-231 human breast cancer cells, showing that CTC clusters are oligoclonal and tumor xenografts of LM2 variant of MDA-MB-231 human breast cancer cells endow/possess (Jolly and Celià-Terrassa, 2019).

The interconnection between CTC, EMT and CSC has been actively studied and reported to harbor important mechanisms underlying tumorigenicity (Agnoletto et al., 2019). EMT generates stem-like cells (Mani et al., 2008) and tumor cells that features both EMT and stem-like characters are better equipped to induce metastasis (May et al., 2011; Barriere et al., 2014), while some CTCs have dynamic cellular plasticity expressing EMT traits and stemnicity (Alonso-Alconada et al., 2014). A minor fraction of EMT hybrid phenotype CTCs have been shown to exhibit stem-like features, and these cells have been shown to promote collective migration Kaigorodova et al. (2017); Quan et al. (2020), as well as enhanced survivability and chemoresistant (Papadaki et al., 2019). Papadaki et al. (2019) modeled four CTC subpopulations based on the co-expression of three different markers; cytokeratin (epithelial marker), ALDH1 (stemness marker) and TWIST1 (partial EMT marker), and revealed that CTCs co-expressing cytokeratin, high levels of ALDH1, and nuclear TWIST1 (CSC+/partial-EMT+) were enriched after the first-line chemotherapy, implying that they were the most chemoresistant subpopulation, and had a favored prognostic value in patients with metastatic breast cancer. Another study has showed that EpCAMhigh CTCs were significantly associated with poor prognosis compared to EpCAMlow CTCs in patients with breast and prostate cancer (de Wit et al., 2018), however the level of mesenchymal co-expression was not measured. Ting et al. (2014) showed that the stem cell markers Aldh1a1 and Aldh1a2 were enriched in pancreatic CTCs, and they also demonstrated that Igfbp5 (a transport protein of epithelial stroma) and SPARC (a collagen-binding glycoprotein related to ECM reorganization) were highly expressed in the CTCs. Although they stated that there was no intrinsic correlation between EMP state and stemness in their CTCs, other reports have shown expression of these genes were associated with Cdh1 reduction (Bradshaw, 2009; Sureshbabu et al., 2012). There still remains a lack of evidence to fully elucidate the mechanistic relationship between CTCs, EMT and CSCs through the association of their existing markers with functional features, although it seems clear that they represent only a small fraction of CTCs.

UNDERSTANDING DYNAMICS OF EMT

In the last two decades, many new concepts and findings have flourished around the dynamics of EMP. The dynamics of the stochastic state transitions, which allows cancer cells to switch between phenotypic states, is not yet explicitly described. However, novel concepts of dynamic equilibrium, asymmetrical dynamics of EMT-MET conversions, bet hedging, and hysteresis/cellular memory of cancer cells have heralded a deeper understanding of the phenotypic heterogeneity that cancer cells endow/possess (Jolly and Celià-Terrassa, 2019).

This intrinsic mechanism of bi-directional transitions between epithelial (differentiated) and mesenchymal (stem-like) states is reported in different kinds of cancer (Polyak and Weinberg, 2009; Chaffer et al., 2011; Gupta et al., 2011; Yang et al., 2012; Ruscetti et al., 2016; Bhatia et al., 2019). Sequencing of breast cancer stem cell populations also indicates a dynamic conversion between differentiation states in vivo (Klevêbring et al., 2014). A phenotypically stable equilibrium was observed in breast cancer cell lines, differentially segregated across cell state proportions (Gupta et al., 2011; Bhatia et al., 2019).

DNA barcoding and subsequently high-throughput sequencing of breast cancer cell clones had also been employed to quantify the extent of intrinsic phenotypic plasticity exhibiting epithelial or mesenchymal phenotypes (Mathis et al., 2017; Rios et al., 2019). Various mechanism-based mathematical modeling and data-based statistical modeling approaches have been developed in an attempt to uncover the presence of these metastable states (Lu et al., 2013; Jolly et al., 2016; Jolly and Celià-Terrassa, 2019).

The presence of “multiple attractor states” based on Waddington landscape and intrinsic cellular variability also contributes to phenotypic plasticity (Huang et al., 2009; Ferrell, 2012; Li et al., 2016). The studies pertaining to EMT and MET reversion have also explained explicitly that the dynamics achieved for its reversion back may not follow the same path. For example, studies with a Snail-inducible expression system...
in prostate cancer cells has identified metabolic plasticity and asymmetrical dynamics during their EMT-MET cycle (Stylianou et al., 2019). Other studies, where re-expression of significant epithelial markers such as E-cadherin, OVOL2 and GRHL2 after their knockout may not obtain the same spectrum of reversion also suggests asymmetrical dynamics (Qi et al., 2018; Chung et al., 2019; Jolly et al., 2019). The concept of bet hedging had been observed in bacterial persistence under different environmental stimulations by generating mutation-independent phenotypic heterogeneity (Veening et al., 2008). This pre-existing phenotypic heterogeneity is thought to be exploited by cancer cells in generating drug-persistence cells via non-genetic mechanism, which might lead to anti-drug resilience in clinical scenarios (Jolly et al., 2018). The property of hysteresis and “cellular memory” allows cells from the same clonal population to respond differently to the same strength and duration of a signal. The differential response again can be attributed to the cellular placement across different “attractor states” or the possibility of history of input stimuli (Chang et al., 2006; Jolly and Celià-Terrassa, 2019). The possibility of EMT occurring via non-linear hysteretic mode had been recently observed to result in different dynamics and increased metastasis in a breast cancer model (Celià-Terrassa et al., 2018). Thus, these dynamics impart a further layer of intricacies in understanding the causes and reasons of non-genetic heterogeneity in cancer in regard to phenotypic plasticity. An integrative understanding of the approaches to block this phenotypic plasticity and EMP dynamics could further aid in combating cancer resistance.

IMPLICATIONS OF METABOLIC PLASTICITY AND EMP

During the processes of EMP, there are numerous adaptations, not only in cell morphology and epigenetic changes, but also in metabolism (Cha et al., 2015). Among them, glucose and lipid metabolism alterations are crucial for the EMT induction (Kondaveeti et al., 2015; Sánchez-Martínez et al., 2015; Morandi et al., 2017; Kang et al., 2019). In terms of carbohydrate metabolism, it is well known that cancer cells prefer to reply on the glycolysis to generate ATP instead of oxidative phosphorylation (OXPHOS), even under the well-oxygenated conditions, according to the Warburg effect (Warburg, 1956). However, apart from the Warburg effect, other glucose metabolic pathway adaptations have been observed during the last decade. When cancer cells undergo an EMP process, their metabolism will reprogram from aerobic glycolysis for proliferation to EMT-like metabolism to meet the increased energy needs. Both enhanced glucose and lipid uptake and increased glycolytic mediated biosynthesis and lipid synthesis are the characteristics of EMT-like metabolism. The correlation between metabolism and EMP is dynamic. EMP-associated genetic changes can stimulate metabolic adaptations, while the higher metabolic rate can support and facilitate the EMP process.

A number of studies illustrate the EMT-associated metabolic changes and their implications. According to the research of Dong et al., up-regulation of the EMT-driving transcription factor Snail-1 in basal-like breast cancer cells leads to the formation of a Snail-G9a-Dnmt1 complex to silence the expression of fructose-1,6-bisphosphatase (FBP1), which is an important enzyme of gluconeogenesis (Dong C. et al., 2013). The loss of the FBP1 caused an increase in glucose uptake for ATP production and glycolytic mediated biosynthesis, like the pentose phosphate pathway (PPP), serine and glycerol-3-phosphate. The reprogramed metabolism offers enough energy to fuel the invasion and metastasis processes.

For lipid metabolism, higher expression levels of lipid synthesis enzymes such as ATP-citrate lyase (ACLY), stearoyl-CoA desaturase (SCD), fatty acid synthase (FASN) and HMG-CoA reductase, have been detected in more aggressive tumor cells (Sánchez-Martínez et al., 2015). Jing et al. reported that overexpression of these proteins in association with mutated p53 in mostly mesenchymal cancer cells, along with aberrant expression of sterol regulatory element-binding proteins (SREBPs) (Hu et al., 2013). In normal tissue, wild type p53 can inhibit the expression of SREBP-1c, a transcription factor of FASN and ACLY (Horton et al., 2002), while the mutated p53 loses this capacity. Moreover, the mutated p53 can bind with SREBP-2 to enhance the cholesterol biosynthesis (Freed-Pastor et al., 2012). Thus, mutated p53 significantly upregulates both fatty acid (FA) and cholesterol levels in cancer cells, which generate more membrane lipid rafts to support cell motility during the EMT process. High levels of SREBP1 can also induce EMT, via recruiting a SNAIL1/HDAC1/2 complex to stop E-cadherin mRNA expression (Zhang et al., 2019). Chen et al., has proposed that drugs targeting SREBPs could suppress cancer cell metastasis (Chen et al., 2018).

Growth factors from the tumor microenvironment can also reprogram cancer cells from the Warburg-like metabolism to EMT-like metabolism. Activated PI3K/AKT/mTOR signaling due to growth factor stimulation can enhance the uptake of glucose and lipid, as well as the synthesis of FA and protein (Chen et al., 2018). The study of EMP relative metabolism changes can offer a promising target for cancer therapy.

CURRENT MODALITIES TO INVESTIGATE PLASTICITY

Many techniques recently employed in the field of cancer cellular plasticity have corroborated not only the epithelial and mesenchymal phenotypic states, but also the spectrum of intermediate and hybrid E/M states (Pastushenko et al., 2018; Karacosta et al., 2019). The molecular approaches widely used in the cancer EMT field are broadly divided into two categories: in vitro based molecular and functional assays and in vivo based cancer models. The in vitro based assays routinely performed in EMP studies involve various molecular and functional assays. Molecular assays, using FACS and immunocytochemistry staining with microscopy analysis, relies on various validated EMP markers that are used to delineate the phenotypic state of cells (Celià-Terrassa et al., 2018; Pastushenko et al., 2018; Risom et al., 2018; Bhatia et al., 2019). Microscopy based snap-shot and real time analysis in conjunction with quantitative assessment
is an imperative technique. These optic techniques are widely employed to study the cellular localization of various molecular markers, such as E-cadherin presence at the cell junctions, and also the subtle dynamic changes of various markers in the absence or presence of various stimuli or inducers can be studied (Hirata et al., 2014; Labernadie et al., 2017; Liu et al., 2018). Microscopy approaches are also well integrated in various functional assays, such as in vitro wound closure, Transwell migration studies performed in the presence or absence of ECM, quantification of single cell migration and invasion studies in culture medium, spheroid assessment and co-culture assays with cancer associated fibroblasts or endothelial cells (Kramer et al., 2013; Tanner and Gottesman, 2015; Mitchell and O’Neill, 2016; Klymenko et al., 2017; Reynolds et al., 2017; Mason et al., 2019). Other in vitro assessment also include “soft agar assay” for anchorage independent growth studies, “ECM degradation assays” to measure MMP and other protease activity, and “trans-epithelial resistance” assays to study monolayer integrity and permeability (Narai et al., 1997; Anderl et al., 2012; Borowicz et al., 2014). In studies relevant to single cell colonization, plasticity generated from single cell clonal culture is also examined for differences in migration, invasion and chemoresistance assays, which can be extrapolated to the metastatic cascade (Kramer et al., 2013; Harner-Foreman et al., 2017; Bhatia et al., 2019). While in vitro studies are important to study cellular behavior in context of phenotypic plasticity and tumoural non-genetic heterogeneity, these routinely performed assays have the drawback of not presenting the whole landscape of cancer and the real EMP spectrum, where cancer cells are infiltrated with stromal and immune microenvironment.

Researchers in the field of EMP have employed various animal models, including as C. elegans, Drosophila Melanogaster, chick embryos, zebrafish and mice to study the in vivo dynamics of phenotypic plasticity in developmental EMT and cancer EMP (Jimenez et al., 2016; Gómez-Cuadrado et al., 2017; Nieto, 2018; Stuelten et al., 2018; Campbell et al., 2019). Genetically engineered mouse models and patient-derived xenografts (PDXs) have been observed to recapitulate metastatic and organ homing properties similar to clinical specimens (Sikandar et al., 2017). Orthotopic implantation strategies, such as inoculation into the mammary fat pad, has also improved the recapitulation of the breast cancer in mice (Proia et al., 2011). In conjunction with intravital imaging and fluorophore chemistry, various Cre-Lox lineage tracing approaches have been employed in cell lines, and in injected mouse and zebrafish models, to delineate EMP status of the cells at primary and metastatic sites, and also of encapsulated CTCs (Lourenco et al., 2020). These reporter tags are valuable in identification of CTCs and in scenarios of low numbers of cells seeding at secondary niches during metastasis (Zheng et al., 2015; Sikandar et al., 2017). The inducible system utilized for Twist1 induction or deletion at different stages of skin carcinogenesis allowed flexibility in spatio-temporal tuning (Tsai et al., 2012; Beck et al., 2015). The use of confetti mouse models and lineage tracing can also aid in the determination of intratumoural heterogeneity owing to clonal variations, and in fate mapping of the cancer evolution studies (Janiszewska and Polyak, 2018; Marx, 2018; Rios et al., 2019). Technological advances in the fields of single cell transcriptomic analysis (Patel et al., 2014; Ting et al., 2014; Horning et al., 2018; Kim et al., 2018; Puram et al., 2018; Cook and Vanderhyden, 2019), single-cell methylome profiling or ChIP sequencing (Rotem et al., 2015; Angermueller et al., 2016; Grosselin et al., 2019) and multiplex in situ imaging (Tsujikawa et al., 2017; Schulz et al., 2018) has allowed researchers to gain insightful information of cellular phenotypic status from clinical specimens. Microfluidic modalities are also gaining attention recently and are of great help not only in detection and capturing of label-free CTCs from patients, but also to gauge the effects of fluid pressures, cancer cell motility assessment associated with

![FIGURE 2](https://example.com/figure2.png)

**FIGURE 2** | Potential avenues to target EMP. Three main strategies for targeting cancer progression and recurrence with relevance to EMP dynamics are to use agents/compounds (i) that can target the inducers to prevent EMT; (ii) that can selectively kill mesenchymal phenotype and cells present within multiple transition states; (iii) that can revert the cells via MET.
| Target class | Functional class | Drug name | chemotherapeutics combination | Cancer type | Clinical status (first posted, recruitment status) | Intervention/treatment |
|--------------|------------------|-----------|--------------------------------|-------------|----------------------------------------------------|-----------------------|
| TGF-β/TGF-β Receptor inhibitors | Tyrosine kinase inhibitor | LY-2152799 (Galunisertib) | Fluorouracil/Capcitabine + Tumor specific mesorectal excision | Locally Advanced Rectal Adenocarcinoma | NCT02688712 (2016, Recruiting) | Drug: LY2157299 Drug: Capecitabine Drug: Fluorouracil Procedure: Tumor specific mesorectal excision |
| TGF-β receptor inhibitor | TEW-7197 | Pomalidomide | Relapsed or Relapsed and Refractory Multiple Myeloma | Advanced Hepatocellular Carcinoma | NCT02178358 (2014, Active, not recruiting) | Drug: LY2157299 Drug: Sorafenib Drug: Placebo |
| EGF/EGFR Inhibitors | EGF receptor tyrosine kinase inhibitor | Gefitinib | Pemetrexed | Advanced Non-Small Cell Lung Cancer | NCT0182955 (2013, Active, not recruiting) | Drug: Gefitinib Drug: Pemetrexed Drug: Carboplatin |
| | | Pemetrexed, Carboplatin | III B/IV Non-Small Cell Lung Cancer | NCT03151161 (2017, Not yet recruiting) | Drug: Carboplatin |
| | | Cisplatin or Carboplatin | metastatic non-squamous non-small cell lung cancer who did not progress after pemetrexed combined with platinum chemotherapy | NCT03992885 (2019, Recruiting) | Drug: Carboplatin |
| | Apatinib | Pemetrexed, Gemcitabine, Docetaxel | NSCLC Patients Without T790M Mutation | NCT03758677 (2018, Not yet recruiting) | Drug: Apatinib Drug: Chemotherapy with platinum-based double drugs (Pemetrexed, Gemcitabine, Docetaxel) |
| | | Pemetrexed Plus Carboplatin | Advanced Non-small Cell Lung Cancer | NCT03164694 (2018, Recruiting) | Drug: Apatinib + Pemetrexed + Carboplatin Drug: Pemetrexed + Carboplatin |
| | Osimertinib | Cisplatin or Carboplatin | Metastatic EGFR Mutant Lung Cancers | NCT03567642 (2018, Recruiting) | Drug: Osimertinib Drug: Platinum Drug: Etoposide |
| | | Platinum-based Doublet-Chemotherapy | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT02151981 (2018, Active, not recruiting) | Drug: Chemotherapy Drug: Cross-over to Osimertinib |
| | | Pemetrexed + Cisplatin or Pemetrexed + Carboplatin | Locally Advanced Non-Small Cell Lung Cancer | NCT0405486 (2019, Recruiting) | Drug: Osimertinib Drug: Osimertinib + Pemetrexed + Cisplatin Drug: Osimertinib + Pemetrexed + Carboplatin |
| Monoclonal antibody | Panitumumab | Carboplatin and Paclitaxel | Invasive Triple Negative Breast Cancer | NCT0287610 (2016, recruiting) | Drug: Carboplatin Other: Laboratory Biomarker Analysis Drug: Paclitaxel Biological: Panitumumab |
| | | Carboplatin + Paclitaxel | Advanced Solid Tumors | NCT03577704 (2018, Recruiting) | Drug: HLX07 + Gemcitabine + Cisplatin Drug: HLX07 + Paclitaxel + Carboplatin Drug: HLX07 + mFOLFOX6 |
TABLE 2 | Different categories of inhibitors that target stimuli and signaling pathways associated with EMT and are targeted in current clinical trials.

| Target class               | Functional class                      | Drug Name          | Cancer type                                                                 | Clinical status (first posted) |
|----------------------------|---------------------------------------|--------------------|-------------------------------------------------------------------------------|--------------------------------|
| Inhibitors of extracellular mediators and their corresponding receptors | TGF-β-TGF-β receptor inhibitors | TGF-β receptor inhibitor TEW-7197 | Urothelial Carcinoma, Recurrent, Advanced, Urothelial Carcinoma, Myelodysplastic Syndromes | NCT04064190(2019); NCT03074006(2017) |
|                           | TGFβ receptor ectodomain-IgG Fc fusion protein | AVID200 | refractory advanced and metastatic malignancies, Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118) | NCT03834662(2019); NCT03895112(2019) |
|                           | a bifunctional fusion protein targeting PD-L1 and TGF-β | MSB0011359C (M7824) | Stage II-III HER2 Positive Breast Cancer, Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer), Solid Tumors, Recurrent Respiratory Papillomatosis, HPV Associated Malignancies | NCT03620201(2018); NCT03833661(2019); NCT02698515(2016); NCT02517398(2015); NCT03707587(2018); NCT03427411(2018) |
|                           | CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART) | GPC3-T2-CAR-T | Hepatocellular Carcinoma, Squamous Cell Lung Cancer | NCT03198546(2017) |
| IL-6/IL-6R inhibitors     | Monoclonal antibody                  | Siltuximab (CNTO-328, Tocilizumab) | Metastatic Pancreatic Cancer, multiple myeloma (MM) and systemic AL amyloidosis (AL) | NCT04191421(2019); NCT03315026(2017) |
| EGF/EGFR inhibitors       | Tyrosine kinase inhibitor            | Afatinib (BIBW2992) | Chordoma, | NCT03083678(2018) |
|                           | Dacomitinib (PF00299804)             | | EGFR Mutant Lung Cancer | NCT03755102(2018) |
|                           | Osimertinib                          | | Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer, stage IIIB-IV or Recurrent Non-small Cell Lung Cancer | NCT03586453(2018); NCT03434418(2018); NCT03433469(2018); NCT03191149(2018) |
|                           | Brigatinib (AP26113)                 | | Advanced Non-small Cell Lung Cancer (NSCLC), Anaplastic Large Cell Lymphoma, Advanced Malignant Neoplasm | NCT02737501(2016); NCT02706626(2017); NCT03719898(2018); NCT03888423(2019); NCT03707938(2018); NCT03596866(2019) |
|                           | inhibitor for (EGFR, HER2, and ErbB4) | Poziotinib (HM761-36B) | EGFR Exon 20 Mutant Advanced NSCLC, Breast Cancer, Stage IV Lung Adenocarcinoma with HER2 Mutation | NCT03066206(2017); NCT03744715(2018); NCT03318939(2017); NCT02979821(2016) |
|                           | Monoclonal antibody                  | Panitumumab        | Anaplastic Lymphoma Kinase-Positive (ALK +), Advanced Non-Small-Cell Lung Cancer (NSCLC) | NCT03535740(2019) |
|                           | PDGF/PDGF receptor inhibitors       | Tyrosine kinase inhibitor | Axitinib | Advanced Biliary Tract Cancer, Thyroid Neoplasms, Advanced Gastric Cancer, Non-small Cell Lung Cancer, Solid Tumor, Thyroid Cancer | NCT02684890(2016); NCT03839489(2019); NCT03494816(2018); NCT04010071(2019); NCT03826589(2019); NCT03472560(2018); NCT03341845(2017) |
|                           | Tyrosine kinase inhibitor            | Lenvatinib         | Advanced Biliary Tract Cancer, Thyroid Neoplasms, Advanced Gastric Cancer, Non-small Cell Lung Cancer, Solid Tumor, Thyroid Cancer | NCT04211168(2019); NCT03573960(2018); NCT03609359(2018); NCT03929332(2019); NCT03090929(2017); NCT03313974(2017) |
|                           | FGF/FGFR inhibitors                  | Tyrosine kinase inhibitor | Nintedanib (BIBF1120) | Appendix Cancer, Lymphangioleiomyomatosis, Adenocarcinoma of the Lung | NCT03287447(2017); NCT03629432(2017); NCT04046614(2019) |
|                           |                                     | Pazopanib          | Refractory Solid Tumors, Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma, Advanced Renal Cell Carcinoma Metastatic Renal Cell Carcinoma | NCT02691767(2016); NCT04199026(2019); NCT03200717(2017) |

(Continued)
| Target class                        | Functional class                                                                 | Drug Name          | Cancer type                                                                                                                                  | Clinical status (first posted)          |
|------------------------------------|----------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Ponatinib                          | Medullary Thyroid Cancer, Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, GIST, Malignant, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | NCT03383692(2019); NCT03934372(2019); NCT03171389(2017); NCT04233346(2020); NCT03709017(2018) |
| Infliximab                         | Advanced Melanoma                                                                | NCT03293784(2017) |
| Vismodegib                         | Stomach Neoplasms, Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Advanced Solid Tumors | NCT03052478(2017); NCT03053188(2017); NCT03861002(2018); NCT03297606(2017) |
| Sonidegib                          | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Basal Cell Carcinoma | NCT04007744(2019); NCT04066504(2019) |
| γ-secretase inhibitor:             | Advanced Solid Tumor                                                             | NCT02836600(2016) |
| Foxy-5                             | Colon Cancer                                                                     | NCT03838902(2019) |
| Wnt5a mimetic                      | Advanced Solid Tumors, Advanced Breast Cancer                                    | NCT02411145(2019); NCT02546531(2015) |
| BMS-90624                          | colon Cancer                                                                     | NCT03970606(2017) |
| Idelalisib                          | Follicular Non-Hodgkin's Lymphoma Refractory, Relapsed Diffuse Large B-cell Lymphoma, B-cell Lymphoma Recurrent, B-cell Chronic Lymphocytic Leukemia | NCT03569993(2019); NCT04196599(2019) |
| AZD5363                            | Advanced Solid Tumors, Advanced Breast Cancer                                    | NCT03316541(2017); NCT03182634(2017) |
| Teratinimus                        | Non-muscle Invasive Bladder Cancer, Ascites                                        | NCT02753309(2016) |
| Cx-4945                            | Recurrent Medulloblastoma                                                         | NCT03964862(2019) |
| BGB324                             | Recurrent Glialblasta Undergoing Surgery, Advanced NSCLC                          | NCT03965494(2019); NCT03184571(2017) |
| Trametinib                         | Advanced ALK-Positive NSCLC, Advanced Metastatic Colorectal Cancer                | NCT03087448(2017); NCT03714968(2018) |
| JAK and STAT3 inhibitors           | STAT3: BB1608 (Napabucasin)                                                      | NCT03522649(2018); NCT03867839(2018); NCT03717444(2018) |
single cell or collective migration, and for co-culture studies (Sarioğlu et al., 2015; Ma et al., 2018; Shang et al., 2019; Truong et al., 2019). Similarly, various mathematical approaches and modeling have been helpful in deciphering the significant genes and molecular networks associated with the spectrum of epithelial and mesenchymal states, as well as phenotypic plasticity (Jolly et al., 2017; Bocci et al., 2018; Jia et al., 2019; Yang et al., 2019). However, it is crucial to acknowledge that the modalities and analytical approaches utilized in the field of EMP present context-specific studies, such that inferences derived will not provide an overarching conclusion (Henkel et al., 2019). Inherent limitations of the employed assays should always be taken into consideration while extrapolating from the data.

THERAPEUTIC STRATEGIES FOR TARGETING EMP

The presence of plasticity in tumor cells and resultant heterogeneity is one of the utmost challenges in targeting cancer on a whole (Bhatia et al., 2017; Redfern et al., 2018). EMT and/or CSC have been reported to confer drug resistance characteristics against a number of conventional therapeutics like taxol, vincristine, oxaliplatin, gemcitabine, cisplatin and 5-fluorouracil in human pancreatic cell lines, and against EGFR-targeted therapies erlotinib, cetuximab and gefitinib in lung cancer (Fuchs et al., 2008; Sabbah et al., 2008; Arumugam et al., 2009). Similarly, studies have also reported that an active EMT program in breast cancer cell lines makes them unresponsive to tamoxifen, paclitaxel, and adriamycin treatment (Kajita et al., 2004; Hiscox et al., 2006; Cheng et al., 2007; Li Q. Q. et al., 2009). Breast cancer cells with EMT-associated CSC features (CD44high, CD24low) have been reported to remain after neoadjuvant chemotherapy and HER2 pharmacological inhibition, suggesting that they encode resistance (Li et al., 2008; Blick et al., 2010). Many reports have also shown basal, mesenchymal-like neoplasms to be more resistant to neoadjuvant chemotherapy than epithelial, luminal-like tumors (Yauch et al., 2005; Carey et al., 2007; Liedtke et al., 2008), and reversal of the EMT phenotype in resistant cell lines has re-established drug sensitivity (Arumugam et al., 2009; Li Y. et al., 2009). Therefore, three main strategies as combinatorial therapies that are being widely acknowledged and/or proposed in the field of combating plasticity are (i) Targeting EMP inducing stimuli which can prevent mesenchymal transitioning, (ii) Targeting the cells, specifically in mesenchymal or hybrid state which can inhibit MET at secondary niche, and (iii) Reverting the mesenchymal cells back to the epithelial state (Bhatia et al., 2017; Williams et al., 2019; Figure 2).

In the first scenario to target EMP inducing stimuli, many different approaches have been utilized to inhibit different signaling pathways that contribute to the induction and maintenance of EMT, such as TGFβ/TGFβR, EGF/EGFR, FGF/FGFR, IGF/IGFR, IL-6/IL-6R, HGF/MET, PDGF/PDGFR, TNFα, Wnt and Notch signaling (Marcucci et al., 2016; Bhatia et al., 2017). Of all, TGFβ and EGF pathway inhibitors have been most extensively studied and investigated, as these have been found to be common inducers of EMT in different cancer types (Li et al., 2015). Table 1 details the current active clinical trials inhibiting these two EMT-inducing pathways in combination with chemotherapeutics.

Secondly, for therapies specifically targeting mesenchymal cells, different novel strategies such as EMP-targeting vaccines against transcription factors such as TWIST1 and Brachyury;

| Target class | Functional class | Drug Name | Cancer type | Clinical status (first posted) |
|-------------|-----------------|-----------|-------------|-------------------------------|
| Histone deacetylase inhibitor | Vorinostat | Mutated Advanced Melanoma, Breast Cancer | NCT02836548(2016); NCT03742245(2018) |
| Romidepsin | Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma | NCT03742921(2018); NCT03547700(2018) |
| Mocetinostat | Advanced Lung Cancer, Unresectable Stage III or Stage IV Melanoma | NCT03220477(2017); NCT03586406(2018) |
| Panobinostat | Multiple Myeloma | NCT02722941(2016); NCT04150289(2019) |
| Histone methyl transferases inhibitor | EZH2 inhibitor | E7438 (Tazemetostat, EPZ-6438) | Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma, Relapsed/Refractory Follicular Lymphoma | NCT03030934(2017); NCT03456725(2018); NCT04224839(2020) |
| EZH1/2 inhibitor | DS-3301b | Relapsed or Refractory Adult T-cell Leukemia/Lymphoma, Acute Leukemia Myeloid Leukemia, Acute Lymphocytic, Recurrent Small Cell Lung Cancer | NCT04121500(2019); NCT03110354(2019); NCT03879798(2019) |
| Inhibitors of stimuli from the tumor microenvironment | HIF-1α inhibitors | Small molecule inhibitor | PT2385 | Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma, Recurrent Glioblastoma | NCT03108066(2017); NCT03216499(2017) |
| | | | | Breast Cancer, Circulating Tumor Cells (CTCs), Advanced Pancreatic Cancer, Advanced Solid Tumor | NCT03992820(2019); NCT03889795(2019) |
The crucial roles of EMT-MET during embryogenesis and organogenesis is hijacked during tumor progression and metastasis. The roles of various signaling cascades, intrinsic and extrinsic mechanisms, and regulators that contributes to EMP dynamics are reasonably well determined, but more refined studies and techniques need to be employed to recapitulate the MET behavior of cells while extravasating, seeding and colonizing at secondary niches. The intricacies associated with phenotypic plasticity, stemness and intratumoral heterogeneity further sheds light on several unresolved queries. The reliable features of cellular behavior relating to drug persistent states through the spectrum of EMT need to be verified. Is there a ubiquitous molecular feature of partial/hybrid EMT cells that can be identified and targeted across all different cancer context types? What actual mechanisms do cancer cells employ to intravasate from the primary sites, and how do EMT - MET programs cooperate to assist cancer cells through several stages of cancer progression? We are still lagging in obtaining a wider and more complete understanding of the contributions of EMP in cancer. The sophisticated developments in lineage tracing using confetti animal models and implementation of other novel technologies such as high-resolution intravital imaging, live cell imaging, inducible reporter systems and single-cell sequencing techniques will provide great avenues in the fields of plasticity and dynamics around EMP. Finally, it is imperative to determine how phenotypic plasticity can be exploited, as therapeutic interventions that push the conversion of cancer cells to fat cells or apoptosis, for example, (David et al., 2016; Ishay-Ronen et al., 2019) might be promising approaches in clinical settings.

CONCLUSION AND PERSPECTIVES

The crucial roles of EMT-MET during embryogenesis and organogenesis is hijacked during tumor progression and metastasis. The roles of various signaling cascades, intrinsic and extrinsic mechanisms, and regulators that contributes to EMP dynamics are reasonably well determined, but more refined studies and techniques need to be employed to recapitulate the MET behavior of cells while extravasating, seeding and colonizing at secondary niches. The intricacies associated with phenotypic plasticity, stemness and intratumoral heterogeneity further sheds light on several unresolved queries. The reliable features of cellular behavior relating to drug persistent states through the spectrum of EMT need to be verified. Is there a ubiquitous molecular feature of partial/hybrid EMT cells that can be identified and targeted across all different cancer context types? What actual mechanisms do cancer cells employ to intravasate from the primary sites, and how do EMT - MET programs cooperate to assist cancer cells through several stages of cancer progression? We are still lagging in obtaining a wider and more complete understanding of the contributions of EMP in cancer. The sophisticated developments in lineage tracing using confetti animal models and implementation of other novel technologies such as high-resolution intravital imaging, live cell imaging, inducible reporter systems and single-cell sequencing techniques will provide great avenues in the fields of plasticity and dynamics around EMP. Finally, it is imperative to determine how phenotypic plasticity can be exploited, as therapeutic interventions that push the conversion of cancer cells to fat cells or apoptosis, for example, (David et al., 2016; Ishay-Ronen et al., 2019) might be promising approaches in clinical settings.

AUTHOR CONTRIBUTIONS

SB wrote the manuscript, developed the first draft, and contributed significantly toward development of the whole manuscript. PW contributed significantly in content material, figures and tables preparation and drafted metabolomics section. AT contributed in providing content material and drafted CTC section. ET refined, edited the manuscript, and approved the final version to be published.

FUNDING

During the course of study, SB, PW and AT were supported by a QUTPRA scholarship.

REFERENCES

Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., et al. (2014). Circulating tumor cell clusters are oligodendroglial precursors of breast cancer metastasis. Cell 158, 1110–1122. doi: 10.1016/j.cell.2014.07.013
Agnoletto, C., Corrà, F., Minotti, L., Baldassari, F., Crudelle, F., Cook, W. J. J., et al. (2019). Heterogeneity in circulating tumor cells: the relevance of the stem-cell subset. Cancer 11:483. doi: 10.3390/cancers11040483
Aiello, N. M., Brabietz, T., Kang, Y., Nieto, M. A., Weinberg, R. A., and Stanger, B. Z. (2017). Upholding a role for EMT in pancreatic cancer metastasis. Nature 547, E7–E8. doi: 10.1038/nature22963
Aiello, N. M., and Kang, Y. (2019). Context-dependent EMT programs in cancer metastasis. J. Exp. Med. 216, 1016–1026. doi: 10.1084/jem.20181827

FUNDING

During the course of study, SB, PW and AT were supported by a QUTPRA scholarship.
Bhattacharya, M. K., Cheng, G. Z., Zhang, W., Shi, J., Gross, J. S., and Wang, L. H. (2019). Metabolic shifts associated with epithelial-mesenchymal transition. Cancer Res. 79, 1105–1116. doi: 10.1158/0008-5472.can-18-1993

Bocci, F., Jolly, M. K., George, J. T., Levine, H., and Onuchic, J. N. (2018). The role of genetic instability in tumor progression. Cancer Res. 78, 3691–3701. doi: 10.1158/0008-5472.can-17-3955

Boilling, T., Wiskott, A., and Lütolf, M. (2016). Circulating tumor cells and epithelial-mesenchymal transition contribute to drug resistance in pancreatic cancer. Cancer Res. 76, 593–602. doi: 10.1158/0008-5472.can-15-2753

Bolwell, G. P., and Kursar, T. A. (2017). Plant cell wall biology. Annu. Rev. Plant Biol. 68, 569–592. doi: 10.1146/annurev-arplant-050516-042447

Bleicher, E., Battaglia, G., and Ellis, P. (2011). HER2 status and circulating tumor cells. Cancer Res. 71, 4979–4983. doi: 10.1158/0008-5472.can-11-1386

Blumenfeld, A., and Kaelin, W. G. (2012). The role of NOTCH signaling in cancer. Nat. Rev. Cancer 12, 451–463. doi: 10.1038/nrc3265

Bocchi, S., Slotte, M., and Kalluri, R. (2011). Circulating tumor cells in cancer metastasis. Trends Mol. Med. 17, 463–473. doi: 10.1016/j.molmed.2011.06.005

Bocchi, S., and Kalluri, R. (2010). Circulating tumor cells as biomarkers for cancer diagnosis and therapy. J. Cell Biol. 190, 319–328. doi: 10.1083/jcb.200912109

Bocchi, S., and Kalluri, R. (2009). Circulating tumor cells in cancer metastasis. Cancer Res. 69, 5820–5828. doi: 10.1158/0008-5472.can-08-0425

Bocchi, S., and Kalluri, R. (2008). Circulating tumor cells in cancer metastasis. Cancer Res. 68, 7809–7812. doi: 10.1158/0008-5472.can-08-1251

Bocchi, S., and Kalluri, R. (2007). Circulating tumor cells in cancer metastasis. Cancer Res. 67, 8742–8751.

Bocchi, S., and Kalluri, R. (2006). Circulating tumor cells in cancer metastasis. Cancer Res. 66, 8742–8751.

Bocchi, S., and Kalluri, R. (2005). Circulating tumor cells in cancer metastasis. Cancer Res. 65, 8742–8751.

Bocchi, S., and Kalluri, R. (2004). Circulating tumor cells in cancer metastasis. Cancer Res. 64, 8742–8751.

Bocchi, S., and Kalluri, R. (2003). Circulating tumor cells in cancer metastasis. Cancer Res. 63, 8742–8751.

Bocchi, S., and Kalluri, R. (2002). Circulating tumor cells in cancer metastasis. Cancer Res. 62, 8742–8751.

Bocchi, S., and Kalluri, R. (2001). Circulating tumor cells in cancer metastasis. Cancer Res. 61, 8742–8751.

Bocchi, S., and Kalluri, R. (2000). Circulating tumor cells in cancer metastasis. Cancer Res. 60, 8742–8751.

Bocchi, S., and Kalluri, R. (1999). Circulating tumor cells in cancer metastasis. Cancer Res. 59, 8742–8751.
ZEB1 expression during epithelial to mesenchymal transition. *J. Biol. Chem.* 286, 12024–12032. doi: 10.1074/jbc.M110.168625

David, C. J., Huang, Y.-H., Chen, M., Su, J., Zou, Y., Bardeesy, N., et al. (2016). TGF-β Tumor Suppression through a Lethal EMT. *Cell* 164, 1015–1030. doi: 10.1016/j.cell.2016.02.009

de Wit, S., Manicone, M., Rossi, E., Lampignano, R., Yang, L., Zill, B., et al. (2018). EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients. *Oncoarget* 9,35705.

Debaugnies, M., Sánchez-Danés, A., Rorive, S., Raphael, M., Liagre, M., Parent, M.-A., et al. (2018). YAP and TAZ are essential for basal and squamous cell carcinoma initiation. *EMBO Rep.* 19, e45809. doi: 10.15252/embr.201845809

Devarajan, E., Song, Y. H., Krishnappa, S., and Alt, E. (2012). Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGFD release by tissue-resident stem cells. *Int. J. Cancer* 131, 1023–1031. doi: 10.1002/ijc.26493

Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T. W., Miriyala, S., et al. (2013). Loss of FBPI by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. *Cancer Cell* 23, 316–331. doi: 10.1016/j.ccr.2013.01.022

Dong, P., Karaayvaz, M., Jia, N., Kaneuchi, M., Hamada, J., Watari, H., et al. (2013). Loss of tumor cells in patients with pancreatic cancer: a meta-analysis. *Int. J. Cancer* 132, 3286–3295. doi: 10.1002/ijc.26493

Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., et al. (2017). Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. *Cancer Res.* 77, 3982–3989. doi: 10.1158/0008-5472.can-16-1592

Ferrell, J. E. Jr. (2012). Bistability, bifurcations, and Waddington’s epigenetic landscape. *Curr. Biol.* 22, R458-R466. doi: 10.1016/j.cub.2012.03.045

Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T., et al. (2015). Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. *Nature* 527, 472–476. doi: 10.1038/ nature15748

Franclant, M.-E., Lambert, J., Vanwynsberghe, A. M., Thompson, E. W., Bourcy, M., Polette, M., et al. (2018). Epithelial-mesenchymal plasticity and circulating tumor cells: travel companions to metastasis. *Dev. Dyn.* 247, 432–450. doi: 10.1002/dvdy.24506

Freed-Pastor, W. A., Mizuno, H., Zha, X., Langerod, A., Rodriguez-Barrueco, R., et al. (2012). Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. *Oncogene* 32, 3286–3295. doi: 10.1038/onc.2012.334

Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., et al. (2017). Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. *Cancer Res.* 77, 3982–3989. doi: 10.1158/0008-5472.can-16-1592

Huang, S., Ernberg, I., and Kauffman, S. (2009). Cancer attractors: a systems view of cancer epithelial-mesenchymal plasticity and its association with stemness and metastasis. *Nature* 457, 472–476. doi: 10.1038/nature15748

Huang, S., Ernberg, I., and Kauffman, S. (2009). Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. *Semin. Cell Dev. Biol.* 20, 869–876. doi: 10.1016/j.semcdb.2009.07.003

Hugo, H., Ackland, M. L., Blick, T., Lawrence, M. G., Clements, J. A., Williams, E. D., et al. (2007). Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. *J. Cell. Physiol.* 213, 374–383. doi: 10.1002/jcp.21223

Hu, J., Liu, Z., and Wang, X. (2013). Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism? *Med. Hypotheses* 81, 513–520. doi: 10.1016/j.mehy.2013.06.009

Huang, R. Y. J., Wang, M. K., Tan, T. Z., Kuay, K. T., Ng, A. H. C., Chung, V. Y., et al. (2013). An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src kinase inhibitor, saracatinib (AZD0530). *Cell Death Dis.* 4:e915. doi: 10.1038/cddis.2013.442

Huang, S., Ernberg, I., and Kauffman, S. (2009). Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. *Semin. Cell Dev. Biol.* 20, 869–876. doi: 10.1016/j.semcdb.2009.07.003

Hugo, H., Ackland, M. L., Blick, T., Lawrence, M. G., Clements, J. A., Williams, E. D., et al. (2007). Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. *J. Cell. Physiol.* 213, 374–383. doi: 10.1002/jcp.21223

Huang, S., Ernberg, I., and Kauffman, S. (2009). Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. *Semin. Cell Dev. Biol.* 20, 869–876. doi: 10.1016/j.semcdb.2009.07.003

Hugo, H., Ackland, M. L., Blick, T., Lawrence, M. G., Clements, J. A., Williams, E. D., et al. (2007). Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. *J. Cell. Physiol.* 213, 374–383. doi: 10.1002/jcp.21223

Hug, S., Ackland, M. L., Blick, T., Lawrence, M. G., Clements, J. A., Williams, E. D., et al. (2007). Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. *J. Cell. Physiol.* 213, 374–383. doi: 10.1002/jcp.21223
Kurimoto, R., Iwasawa, S., Ebata, T., Ishiwata, T., Sekine, I., Tada, Y., et al. (2016). Drug resistance originating from a TGF-beta/FGF-2 driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFRT mutation. Int. J. Oncol. 48, 1825–1836. doi: 10.3892/ijo2016.3419

Labradoris, A., Kato, T., Brugués, A., Serra-Picamal, X., Derzsi, S., Arwert, E., et al. (2017). A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat. Cell Biol. 19, 224–237. doi: 10.1038/nccb3478

Lambert, A. W., Pattabiraman, D. R., and Weinberg, R. A. J. C. (2017). Emerging biological principles of metastasis. Cell 168, 670–691. doi: 10.1016/j.cell.2016.11.037

Latil, M., Nassar, D., Beck, B., Boumahdi, S., Wang, L., Brisebarre, A., et al. (2017). Cell-type-specific chromatin states differentially prime squamous cell carcinoma tumor-initiating cells for epithelial to mesenchymal transition. Cell Stem Cell 20, 191–204. doi: 10.1016/j.stem.2016.10.018

Lechappertier, A., Vielh, P., Perez-Moreno, P., Planchard, D., Soria, J., and Farace, F. J. B. (2011). Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br. J. Cancer 105, 1338–1341. doi: 10.1038/bjc.2011.405

Lee, J. M., Dedhar, S., Kalluri, R., and Thompson, E. W. (2006). The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172, 973–981. doi: 10.1083/jcb.200601018

Lee, S. Y., Ju, M. K., Jeon, H. M., Lee, Y. J., Kim, C. H., Park, H. G., et al. (2018). Oncogenic metabolism acts as a prerequisite step for induction of cancer metastasis and cancer stem cell phenotype. Oxid. Med. Cell Longev. 2018, 1027453. doi: 10.1155/2018/1027453

Lemaire, C. A., Liu, S. Z., Wilkerson, C. L., Ramani, V. C., Barzanzian, N. A., Huang, K.-W., et al. (2018). Fast and label-free isolation of circulating tumor cells from blood: from a research microfluidic platform to an automated fluidic instrument, VTX-1 liquid biopsy system. SLAS Technol. 23, 16–29. doi: 10.1177/2166402318815167

Li, L., Qin, L., Liang, Z., Song, W., Liu, Y., Wang, Y., et al. (2015). Transforming growth factor-beta induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells. Int. J. Mol. Med. 36, 113–122. doi: 10.3892/ijmm.2015.2222

Li, Q., Wennborg, A., Aurell, E., Dede, L., Zou, J.-Z., Xu, Y., et al. (2016). Dynamics inside the cancer cell attractor reveal cell heterogeneity, limits of stability, and escape. Proc. Natl. Acad. Sci. U.S.A. 113, 2627–2632. doi: 10.1073/pnas.1519211113

Li, Q., Xu, J. D., Wang, W. J., Cao, X. X., Chen, Q., Tang, F., et al. (2009). Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer Res. 15, 2657–2665. doi: 10.1158/1078-0432.ccr-08-2372

Li, M., Yoon, S. J., Shin, J. Y., Seo, C. Y., Park, S. M., Kim, J. Y., et al. (2018). Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 69, 6704–6712. doi: 10.1158/0008-5472.can-10-0929

Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M. F., et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100, 672–679. doi: 10.1093/jnci/djn123

Liedtke, C., Mazouini, C., Hess, K. R., Andre, F., Tordai, A., Mejia, J. A., et al. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275–1281. doi: 10.1200/jco.2007.14.4147

Liu, T. L., Upadhysayula, S., Milkie, D. E., Singh, V., Wang, K., Swinburne, I. A., et al. (2013). In vitro cell migration and invasion assays. Mutat. Res. 718, 158–159.

Kondaveeti, V., Guttilla Reed, I. K., and White, B. A. (2015). Epithelial-mesenchymal transition induces similar metabolic alterations in two independent breast cancer cell lines. Cancer Lett. 364, 44–58. doi: 10.1016/j.canlet.2015.04.025

Kowalik, A., Kowalewska, M., and Goźdź, S. J. T. R. (2017). Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solids tumors. Transl. Res. 185, 58–84.

Kramer, N., Walić, A., Unger, C., Rosner, M., Krupitzka, G., Hengstschlager, M., et al. (2013). In vitro cell migration and invasion assays. Mutat. Res. 752, 10–24. doi: 10.1016/j.mrrrev.2012.08.001

Krebs, A. M., Mitschke, J., Laissi Losada, M., Schmalhofer, O., Boerries, M., Busch, H., et al. (2017). The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell Biol. 19, 518–529. doi: 10.1038/nccb3513

Kroger, C., Afeyan, A., Mraz, J., Eaton, E. N., Reinhardt, F., Khodor, Y. L., et al. (2019). Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 116, 7553–7562. doi: 10.1073/pnas.1812877116

Kumar, S., Park, S. H., Cieply, B., Schupp, J., Killiam, E., Zhang, F., et al. (2011). A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol. Cell. Biol. 31, 4036–4051. doi: 10.1128/MCB.01342-1310
cancer metastasis. Cancer Res. 80, 163–169. doi: 10.1158/0008-5472.Can-19-1427

Lu, M., Joly, M. K., Levine, H., Onuchic, J. N., and Ben-Jacob, E. J. P. (2013). MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination. PNAS 110, 18144–18149. doi: 10.1073/pnas.1318192110

Lu, W., and Kang, Y. (2019). Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev. Cell 49, 361–374. doi: 10.1016/j.devcel.2019.04.010

Ma, Y.-H. V., Middleton, K., Levine, H., Onuchic, J. N., and Ben-Jacob, E. J. P. (2018). Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol. Cancer Ther. 17, 437–447. doi: 10.1158/1535-7163.mct-18-0584

Pastushenko, I., and Blanpain, C. (2019). EMT Transition states during tumor progression and metastasis. Trends Cell Biol. 29, 212–226. doi: 10.1016/j.tcb.2018.12.001

Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., et al. (2018). Identification of the tumour transition states occurring during EMT. Nature 556, 463–468. doi: 10.1038/s41586-018-0040-43

Patel, A. P., Tiros, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., et al. (2014). Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401. doi: 10.1126/science.1254257

Pattabiraman, D. R., Bierie, B., Kober, K. I., Thiru, P., Krall, J. A., Zill, C., et al. (2016). Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science 353:3680. doi: 10.1126/science.aad3680

Pattabiraman, D. R., and Weinberg, R. A. (2016). Targeting the Epithelial-to-Mesenchymal Transition: the Case for differentiation-based therapy. Cold. Spring Harb. Symp. Quant. Biol. 81, 11–19. doi: 10.1101/sqb.2016.81.039057

Payne, R., Wang, F., Sun, N., Krell, J., Zebrowski, A., Yagüe, E., et al. (2012). Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients. Br. J. Cancer 106, 1790–1797. doi: 10.1038/bjc.2012.137

Peinado, H., Marin, F., Cubillo, E., Stark, H. J., Fusieng, N., Nieto, M. A., et al. (2004). Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J. Cell Sci. 117(Pt 13), 2827–2839. doi: 10.1242/jcs.01145

Peinado, H., Olmeda, D., and Cano, A. (2007). Snail, Zeb and BHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415–428. doi: 10.1038/nrc2131

Polvak, K., and Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265–273. doi: 10.1038/nrc2620

Proia, T. A., Keller, P. J., Gupta, P. B., Klebba, I., Jones, A. D., Sedic, M., et al. (2011). Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8, 149–163. doi: 10.1016/j.stem.2010.12.007

Narai, A., Arai, S., and Shimizu, M. (1997). Rapid decrease in transepithelial electrical resistance of human intestinal Caco-2 cell monolayers by cytotoxic membrane perturbants. Toxicol. Vitro 11, 347–354. doi: 10.1016/0887-3339(97)00262-x

Nieto, M. A. (2013). Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342:6159.

Nieto, M. A. (2018). A small snail and the chicken embryo. Int. J. Dev. Biol. 62, 121–126. doi: 10.3892/ijd.170301mn

Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., et al. (2017). The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncology 86:1263412. doi: 10.1080/216240216.2016.1263412

Ocana, O. H., Corcoles, R., Fabra, A., Moreno-Bueno, G., Acloque, H., Vega, S., et al. (2012). Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724. doi: 10.1016/j.ccr.2012.10.012

Ochoa-Hernandez, A. B., Vazquez-Zacaria, C. I., Rosales-Reynoso, M. A., and Barros-Nunez, P. (2012). WNT-beta-catenin signaling pathway and its relationship with cancer. Cir. Circ. 80, 389–398.

Oltean, S., Sorg, B. S., Albrecht, T., Bonani, V. I., Brazas, R. M., Dewhirst, M. W., et al. (2006). Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc. Natl. Acad. Sci. U.S.A. 103, 14116–14121. doi: 10.1073/pnas.0603901013

Padmanabhan, V., Krol, I., Suhail, Y., Szczcerba, B. M., Aceto, N., Bader, J. S., et al. (2019). E-cadherin is required for metastasis in multiple models of breast cancer. Nature 573, 439–444. doi: 10.1038/s41586-019-1526-3

Pan, L., Yan, G., Chen, W., Sun, L., Wang, J., and Yang, J. (2019). Distribution of circulating tumour cell phenotype in early cervical cancer. Cancer Manag. Res. 11:5531. doi: 10.2147/cmar.198391

Padapaki, M. A., Stoupis, G., Theodoropoulos, P. A., Mavroudis, D., Georgoulias, V., and Agelaki, S. J. (2019). Circulating tumour cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol. Cancer Ther. 18, 437–447. doi: 10.1158/1535-7163.mct-18-0584
gene expression by pancreatic circulating tumor cells. Cell Rep. 8, 1905–1918. doi: 10.1016/j.celrep.2014.08.029

Truong, D. D., Kratz, A., Park, J. G., Barrientos, E. S., Saini, H., Nguyen, T., et al. (2019). A human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells. Cancer Res. 79, 3139–3151. doi: 10.1158/0008-5472.CAN-18-2293

Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., and Yang, J. (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725–736. doi: 10.1016/j.ccr.2012.09.022

Tsujikawa, T., Kumar, S., Borkar, R. N., Azimi, V., Thibault, G., Chang, Y. H., et al. (2010). Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 5:e8967. doi: 10.1371/journal.pone.0008967

Wallin, J. J., Guan, J., Edgar, K. A., Zhou, W., Francis, R., Torres, A. C., et al. (2012). Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. PLoS One 7:e36402. doi: 10.1371/journal.pone.0036402

Wang, F.-B., Yang, X.-Q., Yang, S., Wang, B.-C., Feng, M.-H., and Tu, J.-C. (2011). A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients—a meta-analysis. Asian Pac. J. Cancer Prev. 12, 2629–2635.

Wang, R., Li, H., Guo, X., Wang, Z., Liang, S., and Dang, C. (2016). IGF-I induces epithelial-to-mesenchymal transition via the IGF-IR-Src-MicroRNA-30a-E-cadherin pathway in nasopharyngeal carcinoma cells. Oncol. Res. 24, 225–231. doi: 10.3727/096504016x14647801447931

Wang, W.-C., Zhang, X.-F., Peng, J., Li, X.-F., Wang, A.-L., Bie, Y.-Q., et al. (2018). Survival mechanisms and influence factors of circulating tumor cells. Biomed. Res. Interna. 2018:9.

Warburg, O. (1956). On the origin of cancer cells. Science 123, 309–314. doi: 10.1126/science.123.3191.309

Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487–1495. doi: 10.1038/ncb1998

Williams, E. D., Gao, D., Redfern, A., and Thompson, E. W. (2019). Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nat. Rev. Cancer 19, 716–732. doi: 10.1038/s41568-019-0213-x

Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., et al. (2006). Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 66, 944–950. doi: 10.1158/0008-5472.can-05-1988

Wong, C. C., Zhang, H., Gilkes, D. M., Chen, J., Wei, H., Chaturvedi, P., et al. (2012). Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J. Mol. Med. 90, 803–815. doi: 10.1007/s00109-011-0855-y

Xu, R., Won, J.-Y., Kim, C.-H., Kim, D.-E., and Yim, H. (2019). Roles of the phosphorylation of transcriptional factors in epithelial-mesenchymal transition. J. Oncol. 2019:5810465. doi: 10.1155/2019/5810465

Yang, G., Quan, Y., Wang, W., Fu, Q., Wu, J., Mei, T., et al. (2012). Dynamic equilibrium between cancer stem cells and non-stem cancer cells in human SW620 and MCF-7 cancer cell populations. Br. J. Cancer 106, 1512–1519. doi: 10.1038/bjc.2012.126

Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., et al. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927–939. doi: 10.1016/j.cell.2004.06.006

Yang, J., and Weinberg, R. A. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818–829. doi: 10.1016/j.devcel.2008.05.009

Yang, Y., Jolly, M. K., and Levine, H. (2019). Computational modeling of collective cell migration: mechanical and biochemical aspects. Adv. Exp. Med. Biol. 1146, 1–11. doi: 10.1007/978-3-030-17593-1_1

Yau, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., et al. (2005). Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11(24 Pt 1), 8686–8698. doi: 10.1158/1078-0432.ccr-05-1492

Ye, X., Brabletz, T., Kang, Y., Longmore, G. D., Nieto, M. A., Stanger, B. Z., et al. (2017). Upholding a role for EMT in breast cancer metastasis. Nature 547, E1–E3. doi: 10.1038/nature22816

Ye, X., Tam, W. L., Shibue, T., Kaygusuz, Y., Reinhardt, F., Ng Eaton, E., et al. (2015). Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256–260. doi: 10.1038/nature14897

Yoo, A. Y., Kang, M. H., Lee, H. J., Kim, B. H., Park, J. K., Kim, H. K., et al. (2011). Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 71, 7061–7070. doi: 10.1158/0008-5472.can-11-1338

Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., et al. (2014). Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216–220. doi: 10.1126/science.1253533

Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., et al. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584. doi: 10.1126/science.1228522

Yuan, X., Wu, H., Han, N., Xu, H., Chu, Q., Yu, S., et al. (2014). Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J. Hematol. Oncol. 7:87. doi: 10.1186/s13045-014-0087-z

Zeisberg, M., Shah, A. A., and Kalluri, R. (2005). Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 280, 8094–8100. doi: 10.1074/jbc.M413102200

Zhang, N., Zhang, H., Liu, Y., Su, P., Zhang, J., Wang, X., et al. (2019). SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. Cell Death Differ. 26, 843–859. doi: 10.1038/s41418-018-0158-158

Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., et al. (2015). Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530. doi: 10.1038/nature16064

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Bhatia, Wang, Toh and Thompson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.